Nisa Investment Advisors, LLC Seagen Inc. Transaction History

Nisa Investment Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	SELL	$191.51 - $216.16 $6,702 - $7,565	-35 Reduced 1.02%	3,400 $721,000
Q1 2023 May 02, 2023	SELL	$127.59 - $203.08 $5,103 - $8,123	-40 Reduced 1.15%	3,435 $695,000
Q4 2022 Feb 02, 2023	SELL	$117.37 - $139.17 $1.46 Million - $1.73 Million	-12,400 Reduced 78.11%	3,475 $447,000
Q3 2022 Nov 07, 2022	BUY	$135.27 - $180.11 $81,973 - $109,146	606 Added 3.97%	15,875 $2.17 Million
Q1 2022 Apr 29, 2022	SELL	$119.61 - $157.85 $471,981 - $622,876	-3,946 Reduced 20.54%	15,269 $2.2 Million

Q4 2021 Feb 03, 2022	SELL	$142.57 - $190.86 $327,768 - $438,787	-2,299 Reduced 10.69%	19,215 $2.59 Million
Q3 2021 Oct 18, 2021	BUY	$142.45 - $169.82 $1.79 Million - $2.14 Million	12,575 Added 140.68%	21,514 $3.65 Million
Q2 2021 Aug 06, 2021	SELL	$135.08 - $161.1 $2.58 Million - $3.08 Million	-19,100 Reduced 68.12%	8,939 $1.41 Million
Q1 2021 Apr 26, 2021	BUY	$137.51 - $190.8 $1.53 Million - $2.12 Million	11,100 Added 65.53%	28,039 $3.89 Million
Q4 2020 Jan 25, 2021	SELL	$164.63 - $211.93 $141,581 - $182,259	-860 Reduced 4.83%	16,939 $2.97 Million
Q3 2020 Oct 20, 2020	BUY	$145.95 - $195.69 $2.6 Million - $3.48 Million	17,799 New	17,799 $3.48 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nisa Investment Advisors, LLC with notifications on news.